Delta-Omicron recombinant escapes therapeutic antibody neutralization
oleh: Ralf Duerr, Hao Zhou, Takuya Tada, Dacia Dimartino, Christian Marier, Paul Zappile, Guiqing Wang, Jonathan Plitnick, Sara B. Griesemer, Roxanne Girardin, Jessica Machowski, Sean Bialosuknia, Erica Lasek-Nesselquist, Samuel L. Hong, Guy Baele, Meike Dittmann, Mila B. Ortigoza, Prithiv J. Prasad, Kathleen McDonough, Nathaniel R. Landau, Kirsten St George, Adriana Heguy
| Format: | Article |
|---|---|
| Diterbitkan: | Elsevier 2023-02-01 |
Deskripsi
Summary: The emergence of recombinant viruses is a threat to public health, as recombination may integrate variant-specific features that together result in escape from treatment or immunity. The selective advantages of recombinant SARS-CoV-2 isolates over their parental lineages remain unknown. We identified a Delta-Omicron (AY.45-BA.1) recombinant in an immunosuppressed transplant recipient treated with monoclonal antibody Sotrovimab. The single recombination breakpoint is located in the spike N-terminal domain adjacent to the Sotrovimab binding site. While Delta and BA.1 are sensitive to Sotrovimab neutralization, the Delta-Omicron recombinant is highly resistant. To our knowledge, this is the first described instance of recombination between circulating SARS-CoV-2 variants as a functional mechanism of resistance to treatment and immune escape.